A randomised phase II study of oxaliplatin alone versus oxaliplatin combined with 5-fluorouracil and folinic acid (Mayo Clinic regimen) in previously untreated metastatic colorectal cancer patients
Alberto Zori Comba, A. Schmilovich, J. Rodger(Instituto de Oncología de Rosario), C. Blajman, Francesc Olivet Pujol(Hospital Alemán), Florencia Perazzo(Centro de Educación Médica e Investigaciones Clínicas Norberto Quirno), Matías Chacón(Instituto Alexander Fleming), Ernesto Wasserman(Merus (Netherlands)), E. Mickiewicz(University of Chicago), Eduardo Cazap(Facultad Latinoamericana de Ciencias Argentina), Eduardo Richardet(Instituto Oncológico de Córdoba), Maximiliano Van Kooten(Universidad Abierta Interamericana), Manuel Vilanova(i3S - Instituto de Investigação e Inovação em Saúde, Universidade do Porto), Federico Cóppola(Hospital Alemán), J. Simon, Francisco Lastiri(Academia Nacional de Medicina), L. Balbiani(Instituto de Oncología de Rosario), S.R. Bella, Maria F. Montiel, Gonzálo Recondo(Centro de Educación Médica e Investigaciones Clínicas Norberto Quirno), R. Giglio
Cited by 37
Related Papers
A Randomized Trial of Exemestane after Two to Three Years of Tamoxifen Therapy in Postmenopausal Women with Primary Breast Cancer
|New England Journal of Medicine|2004|1.8k
Cisplatin and Fluorouracil Alone or with Docetaxel in Head and Neck Cancer
|New England Journal of Medicine|2007|1.7k
Survival and safety of exemestane versus tamoxifen after 2–3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial
|The Lancet|2007|912
Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial
|The Lancet Oncology|2017|496
Activity of Exemestane in Metastatic Breast Cancer After Failure of Nonsteroidal Aromatase Inhibitors: A Phase II Trial
|Journal of Clinical Oncology|2000|318